• Explore /
  • Poster
  • / Indirect treatment comparison (ITC) of momelotinib (MMB) vs fedratinib (FED) safety in patients (pts) with myelofibrosis (MF).

Indirect treatment comparison (ITC) of momelotinib (MMB) vs fedratinib (FED) safety in patients (pts) with myelofibrosis (MF).

Abstract Poster

Authors

null

Lucia Masarova

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

Lucia Masarova , Srdan Verstovsek , Francesca Palandri , Ruben A. Mesa , Claire Harrison , Gautam Sajeev , Boris Gorsh , Ryan Simpson , Sang Kyu Cho , Zhaohui Wang , Catherine Elizabeth Ellis , Seán Conlon , James Signorovitch

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

Track

Hematologic Malignancies

Sub Track

Myeloproliferative Neoplasms (MPN) and Mast Cell Disorders

Clinical Trial Registration Number

NCT04173494; NCT01969838; NCT02101268; NCT01523171; NCT01437787

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 7065)

DOI

10.1200/JCO.2023.41.16_suppl.7065

Abstract #

7065

Poster Bd #

195

Abstract Disclosures

Similar Posters

First Author: Aaron Thomas Gerds

First Author: Vikas Gupta

First Author: Haris Ali

First Author: Ruben A. Mesa